Baseline Characteristics of Patients Randomized in the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study
Key result
The REVERSE trial cohort evaluating cardiac resynchronization therapy included 610 patients with a mean age of 62.5 years who were on better pharmacologic treatment than previous trial cohorts.
Why the study?
Does cardiac resynchronization therapy improve outcomes in patients with asymptomatic left ventricular dysfunction with previous symptoms of mild heart failure?
Population
610 patients with New York Heart Association class II heart failure or asymptomatic LV dysfunction with…
Design
RCT, randomized
Authors
Discussion
Loading...
Member takes
Implication
Supports CRT assessment in milder HF on optimal therapy; extends prior trials to younger patients with narrower QRS.
Study Design
Type
RCT (n=610)
Multicenter
Yes
Structured PICO
Does cardiac resynchronization therapy improve outcomes in patients with asymptomatic left ventricular dysfunction with previous symptoms of mild heart failure?
P
Population
610 patients with New York Heart Association (NYHA) class II (82.3%) heart failure or asymptomatic (NYHA class I) LV dysfunction with previous symptoms (17.7%), mean age 62.5+/-11.0 years, mean LVEF 26.7%+/-7.0%.
I
Intervention
Cardiac resynchronization therapy
O
Outcome
Safety and efficacy
The REVERSE study enrolled a younger, better medically treated cohort with narrower QRS width compared to previous CRT trials, focusing on mild or asymptomatic heart failure.
Cite This Study
Linde et al. (2008) conducted an RCT in Asymptomatic left ventricular dysfunction with previous symptoms of mild heart failure or NYHA class II heart failure (n=610). Cardiac resynchronization therapy was evaluated. The REVERSE trial cohort evaluating cardiac resynchronization therapy included 610 patients with a mean age of 62.5 years who were on better pharmacologic treatment than previous trial cohorts.